Komori
Share Issuance and Disposal130AVeritas In Silico Inc.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 5th Series of Stock Acquisition Rights (with an Exercise Price Adjustment Clause) and the 6th through 9th Series of Stock Acquisition Rights (with a Target Issue and Adjustment Option) (October 2026)

The company reported the October 2026 exercise status of the Fifth through Ninth New Share Warrants. No warrants were exercised during the period, the number of shares delivered was 0, and there was no change in the number of warrants remaining unexercised.

Worth reading
44Recurring
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
0
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status of the Fifth New Share Warrants (with Exercise Price Adjustment Clause) and the Sixth through Ninth New Share Warrants (with Target Issue and Adjustment Options)

発行済株式総数

Exercise ratio for the month: 0.0%

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Fifth: total issued, 30,000 warrants; remaining unexercised at the end of October 2026, 30,000 warrants; Sixth: total issued, 2,000 warrants; remaining unexercised at the end of October 2026, 2,000 warrants; Seventh: total issued, 2,000 warrants; remaining unexercised at the end of October 2026, 2,000 warrants; Eighth: total issued, 1,000 warrants; remaining unexercised at the end of October 2026, 1,000 warrants; Ninth: total issued, 1,000 warrants; remaining unexercised at the end of October 2026, 1,000 warrants
Procedures under the Corporate Code of Conduct
Statement of compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments of New Shares and Other Matters
Most recent equity financing
Fifth through Ninth New Share Warrants issued on 29 October 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status of the Fifth New Share Warrants (with Exercise Price Adjustment Clause) and the Sixth through Ninth New Share Warrants (with Target Issue and Adjustment Options)
Dilution RateExercise ratio for the month: 0.0%
Number of Stock Acquisition RightsFifth: total issued, 30,000 warrants; remaining unexercised at the end of October 2026, 30,000 warrants; Sixth: total issued, 2,000 warrants; remaining unexercised at the end of October 2026, 2,000 warrants; Seventh: total issued, 2,000 warrants; remaining unexercised at the end of October 2026, 2,000 warrants; Eighth: total issued, 1,000 warrants; remaining unexercised at the end of October 2026, 1,000 warrants; Ninth: total issued, 1,000 warrants; remaining unexercised at the end of October 2026, 1,000 warrants
Procedures under the Corporate Code of ConductStatement of compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments of New Shares and Other Matters
Most recent equity financingFifth through Ninth New Share Warrants issued on 29 October 2026
Items this document does not state (23)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This was a report on the monthly exercise status; no reason was given for the lack of exercises.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 5th Series of Stock Acquisition Rights (with an Exercise Price Adjustment Clause) and the 6th through 9th Series of Stock Acquisition Rights (with a Target Issue and Adjustment Option) (October 2026) | Veritas In Silico Inc. (130A) timely disclosure | Komori